Davies, Rowan
Iturriza-Gómara, Miren
Glennon-Alty, Rebecca
Elliot, Alex J.
Vivancos, Roberto
Alvarez Nishio, Anica
Cunliffe, Nigel A.
Hungerford, Daniel
Funding for this research was provided by:
NIHR Health Protection Research Unit in Gastrointestinal Infections
National Institute for Health Research (PDF-2018-11-ST2-006)
Article History
Received: 5 May 2021
Accepted: 21 April 2022
First Online: 13 May 2022
Declarations
:
: This project received ethical approval from the University of Liverpool Health and Life Sciences Research Ethics Committee (Human participants, tissues and databases) (approval number: HLS-7962). The online survey was anonymous and valid informed consent was gained from study participants prior to completion of the questionnaire; recorded using clear affirmative action by use of a consent checkbox. The ethics committee approved this method of valid informed consent.
: Not applicable.
: DH and MIG report grants on the topic of rotavirus vaccines, outside of the submitted work, from GlaxoSmithKline Biologicals, Sanofi Pasteur and Merck and Co (Kenilworth, New Jersey, US) after the closure of Sanofi Pasteur-MSD in December 2016. NAC reports grants on the topic of rotavirus vaccines, outside of the submitted work, from GlaxoSmithKline Biologicals. MIG and NAC also report personal fees for consultancy, outside the submitted work, from GlaxoSmithKline Biologicals. AE, RV, RG-A and RD have nothing to disclose.